"Cervical Cancer, Treatment Without Surgery" Cancer Cell Destruction with BioPlasma

[Financial News]  A new possibility has been suggested that cervical cancer can be treated without surgery through BioPlasma technology.
According to Kyung Hee University Hospital on the 23rd, Professor Kwon Byung-Soo's team from the Department of Obstetrics and Gynecology, in collaboration with Professor Kim Jong-Min from the Department of Life Systems at Sookmyung Women's University and Professor Shim Ga-Yong from the Department of Biomedical Systems at Soongsil University, has identified a biomarker that can predict BioPlasma treatment response for the first time in the world, and confirmed the effects of cancer cell destruction and immune response activation by applying it to cervical cancer treatment.


This research result was published in the June issue of the internationally renowned journal Journal of Controlled Release (IF 11.5).
Cervical cancer can be treated through surgery, radiation, and chemotherapy if detected early, but invasive methods such as removing the uterus or affecting reproductive function can be a significant burden for women of childbearing age.
In response, the research team applied low-temperature non-thermal plasma (NTP) energy to cervical cancer cells and animal (mouse) models to analyze the effects of cancer cell destruction, NTP sensitivity, and the correlation between specific proteins.
The results showed that BioPlasma penetrated up to 5mm deep in patient-derived cervical tissue, directly inducing cancer cell destruction. In particular, it was confirmed to induce immunogenic cell death that activates immune responses, suggesting a positive impact on preventing recurrence after treatment.
The research team confirmed that the lower the expression level of the antioxidant enzyme SOD1, which removes reactive oxygen species within cells, the higher the responsiveness of cancer cells to BioPlasma treatment. This is the world's first identification of a biomarker that can predict BioPlasma treatment response.
Corresponding author Professor Kwon said, "This study not only suggested the possibility of removing cancer cells without surgery but also discovered a biomarker for personalized treatment application, opening the door to precision medicine in the BioPlasma field," and "As more than 35% of cervical cancer patients are women of childbearing age in their 20s to 40s, it is expected that such precision medical technology will become a treatment alternative that preserves fertility."
Meanwhile, Professor Kwon Byung-Soo has founded the BioPlasma specialized medical device company IBMSol to accelerate research on innovative medical technology. Recently, he has developed a non-surgical treatment device 'CureGynPlas' for patients with cervical intraepithelial neoplasia and early cervical cancer and is preparing for clinical trials.

vrdw88@fnnews.com Kang Joong-Mo Reporter